Log in

NASDAQ:MYOSMYOS Stock Price, Forecast & News

$0.88
0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.89
Now: $0.89
$0.92
50-Day Range
$0.89
MA: $1.03
$1.16
52-Week Range
$0.74
Now: $0.89
$1.80
Volume105,026 shs
Average Volume1.27 million shs
Market Capitalization$9.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOS
CUSIPN/A
Phone973-509-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.03 million
Book Value$0.24 per share

Profitability

Net Income$-4,260,000.00
Net Margins-353.71%

Miscellaneous

Employees12
Market Cap$9.76 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive MYOS News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter.

MYOS (NASDAQ:MYOS) Frequently Asked Questions

How has MYOS's stock been impacted by COVID-19 (Coronavirus)?

MYOS's stock was trading at $0.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYOS stock has decreased by 9.7% and is now trading at $0.8850. View which stocks have been most impacted by Coronavirus.

When is MYOS's next earnings date?

MYOS is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for MYOS.

How were MYOS's earnings last quarter?

MYOS Co. (NASDAQ:MYOS) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.29 million for the quarter. MYOS had a negative return on equity of 176.31% and a negative net margin of 353.71%. View MYOS's earnings history.

Has MYOS been receiving favorable news coverage?

News headlines about MYOS stock have been trending somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MYOS earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMYOS.

Are investors shorting MYOS?

MYOS saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 51,400 shares, a decline of 22.4% from the April 15th total of 66,200 shares. Based on an average daily trading volume, of 41,400 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.0% of the shares of the company are short sold. View MYOS's Current Options Chain.

Who are some of MYOS's key competitors?

What other stocks do shareholders of MYOS own?

Who are MYOS's key executives?

MYOS's management team includes the following people:
  • Mr. Joseph Mannello, CEO & Director (Age 61)
  • Mr. Ren Ren, Global Chairman (Age 57)
  • Mr. Joseph DiPietro, Controller
  • Mr. Magshoud Dariani, Chief Technology Officer
  • Mr. Kris Ohrenick, Head of Marketing

What is MYOS's stock symbol?

MYOS trades on the NASDAQ under the ticker symbol "MYOS."

How do I buy shares of MYOS?

Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MYOS's stock price today?

One share of MYOS stock can currently be purchased for approximately $0.89.

How big of a company is MYOS?

MYOS has a market capitalization of $9.76 million and generates $1.03 million in revenue each year. The company earns $-4,260,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. MYOS employs 12 workers across the globe.

What is MYOS's official website?

The official website for MYOS is www.myosrens.com.

How can I contact MYOS?

MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.